Pharmaceutical company Elan has announced an agreement with contract research company PPD.
Under the agreement, PPD will be the main provider of the services needed to develop Elan's products. These include project and data management, biostatistics, clinical and medical monitoring.
Elan says it will retain ownership of its assets and accountability for making decisions on the strategy for its portfolio and individual treatments.
'Establishing this strategic collaboration with PPD will enable Elan to accelerate the progression of our science into the clinical development setting in a rapid and global fashion,' said Eliseo Salinas, Elan's chief medical officer, executive vice president and head of development.
